Has Marie Budev, DO received payments from drug or device companies?

Yes. Drug and device makers reported $158,620 in general payments to Marie Budev, DO across 101 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marie Budev, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marie Budev, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marie Budev, DO

Pulmonary Disease · Cleveland, OHNPI 1528022266

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $117,539 of the $158,620 with a category attached, or 74.1%. 13 manufacturers reported payments, led by Transmedics, Inc. at 34.3% of the total. 2025 is the largest year on record at $58,036, more than ten times the $4,738 reported in 2019. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$158,620in general payments, 2019–2025

Across 101 payments — averaging $1570.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Transmedics, Inc.$54K
United Therapeutics Corporation$51K
Sanofi-aventis U.S. LLC$26K
Sanofi US Services Inc.$8K
Grifols Shared Services North America, Inc.$5K
Boston Scientific$3K
plus $11K from 7 others

$501,222in research payments, 2019–2025

Across 201 payments — averaging $2493.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$428K
Sanofi US Services Inc.$74K

What the payments were for

Consulting fees$117,53974%
Speaking & faculty fees$8,9646%
Travel & lodging$28,47318%
Food & beverage$3,6442%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Transmedics, Inc.	8	$54,392
United Therapeutics Corporation	53	$51,435
Sanofi-aventis U.S. LLC	6	$25,547
Sanofi US Services Inc.	5	$8,102
Grifols Shared Services North America, Inc.	6	$4,608
Boston Scientific	6	$3,412
Zambon USA Ltd.	6	$3,353
Mallinckrodt Hospital Products Inc.	1	$2,320
Kamada Ltd.	2	$2,144
Boehringer Ingelheim	2	$1,785
Xvivo Perfusion Inc.	2	$1,094
La Jolla Pharmaceutical Company	3	$307
Paragonix Technologies, Inc.	1	$122

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$158,620 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio →

Medicare billing

Part B allowed, 2024

$67,093

Medicare patients

Services billed

521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
PrevymisLetermovir	33	$291,459
PertzyeLipase/Protease/Amylase	14	$80,834
NeupogenFilgrastim	11	$24,995
Posaconazole	22	$24,723
Tacrolimus	136	$23,915
Valganciclovir Hcl	57	$18,460
FarxigaDapagliflozin Propanediol	16	$8,983
ColistimethateColistin (Colistimethate Na)	19	$3,385
Azithromycin	167	$3,217
Cyclosporine ModifiedCyclosporine, Modified	19	$3,100
Mycophenolate Mofetil	36	$3,055
Pantoprazole Sodium	124	$2,023
Atorvastatin Calcium	140	$1,498
Ondansetron OdtOndansetron	34	$1,372
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	230	$1,290

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Cleveland

Kristin HighlandCleveland$551K
Joseph CiceniaCleveland$350K
Michael MachuzakCleveland$286K
Leslie TolleCleveland$136K
Elliott DasenbrookCleveland$114K
James StollerCleveland$101K
Gustavo Heresi DavilaCleveland$98K
Bryan BennCleveland$96K
Thomas GildeaCleveland$69K
Daniel CulverCleveland$68K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →